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Tumor metastasis is responsible for the vast majority of cancer-associated morbidities and mortalities.
Recent studies have disclosed the higher metastatic potential of circulating tumor cell (CTC) clusters than
single CTCs. Despite long-term study on metastasis, the characterizations of its most potent cellular
drivers, i.e., CTC clusters have only recently been investigated. The analysis of CTC clusters offers new
intuitions into the mechanism of tumor metastasis and can lead to the development of cancer diagnosis
and prognosis, drug screening, detection of gene mutations, and anti-metastatic therapeutics. In recent
years, considerable attention has been dedicated to the development of efficient methods to separate
CTC clusters from the patients’ blood, mainly through micro technologies based on biological and
physical principles. In this review, we summarize recent developments in CTC clusters with a particular
emphasis on passive separation methods that specifically have been developed for CTC clusters or have
the potential for CTC cluster separation. Methods such as liquid biopsy are of paramount importance for
commercialized healthcare settings. Furthermore, the role of CTC clusters in metastasis, their physical
and biological characteristics, clinical applications and current challenges of this biomarker are thor-
oughly discussed. The current review can shed light on the development of more efficient CTC cluster
separation method that will enhance the pivotal understanding of the metastatic process and may be
practical in contriving new strategies to control and suppress cancer and metastasis.
© 2019 The Authors. Publishing services by Elsevier B.V. on behalf of Vietnam National University, Hanoi.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Metastasis is a complicated, multistep process where cancer
cells detach from the primary tumor, migrate to adjacent tissues,
invade and travel through the bloodstream or the lymphatic sys-
tem, survive, proliferate, colonize in distant organs and finally
establish a new tumor (Fig. 1a) [1e12]. These tumor cells that travel
through the bloodstream or the lymphatic system are called
circulating tumor cells (CTCs).
After decades of research, our understanding of metastasis is
still inconclusive, even though more than a century has been(N. Kashaninejad), mssaidi@
u.au (N.-T. Nguyen).
onal University, Hanoi.
y Elsevier B.V. on behalf of Vietnampassed since the first report of Thomas Ashworth in 1869 on the
presence of circulating tumor cells (CTCs) in the bloodstream
[13e15]. Currently, metastasis is assumed to be responsible for
around 90% of cancer-related deceases [16e18]. Despite decades of
research and experiments, cancer therapies have not been suffi-
cient yet, and themortality rate of cancermetastasis hasmarginally
ameliorated. Mechanistic understanding of the metastasis process
can lead to the development of anti-metastatic therapies that
improve patient mortality [19]. An increasing number of studies
have shown the important role of CTCs in cancer metastases. CTCs
supply more straightforward and comprehensive information
about the tumor [20]. They can be used for various experimental
purposes, e.g., examining the response of cancer cells to chemo-
therapy, predicting the overall survival, noninvasively monitoring
the drug susceptibility, metastatic therapy and as early detection
and prognostic biomarkers [21e25]. Additionally, US food and drug

















Fig. 1. (a) Circulating Tumor Cells (CTCs) detach from primary tumor as single cells and clusters, shed into the bloodstream, and migrate to colonize in distant organs, known as
metastasis. It is assumed 1 ml of blood can comprise 1e10 single CTCs and roughly one CTC cluster, millions of WBCs and billions of RBCs. Copyright © 2017 Vortex Biosciences. (b)
The microenvironment of CTC cluster comprises immune cells, platelets, dendritic cells, cancer-associated fibroblasts, and tumor stroma. Such microenvironment can protect CTC
clusters from blood shear damage and immune attacks that provides CTC cluster metastatic advantages. Reproduced after Vortex Biosciences.
P. Rostami et al. / Journal of Science: Advanced Materials and Devices 4 (2019) 1e182personalized treatment in metastatic colorectal, prostate, and
breast cancers.
Conventional hypotheses assume that metastasis is established
by the invasion and proliferation of individual CTCs into distant
organs after the epithelialemesenchymal transition (EMT), which
increases the invasiveness of the CTCs [26]. However, the discovery
of CTC clusters in clinical and animal models [27], the groups of
two or more tumor cells with strong cellecell contacts, has chal-
lenged this assumption. Individual CTCs might not be the only
cause of metastases; rather, multicellular aggregates of CTCs, CTC
clusters, may play a significant role [28,29]. For the first time, in
1954, Watanabe studied metastasis in mouse model and reported
the higher potential of CTC clusters in tumor metastases [30]. In
the following decades, the 1970s, experimental studies also
demonstrated the higher capacity of CTC clusters in metastases
compared to that of single CTCs. Fidler et al. found that, if cancer
cells were aggregated into clusters before injection, these cells
established several-fold more tumors than the equal numbers of
individual cancer cells [31]. Other researches later confirmed this
finding [32e37].
Based on in-vitro quantification methods, it is known that CTC
clusters comprise 5e20% of the total CTCs depending on the disease
stage in both human and animal models [38e40]. However, a
recent study indicated that the proportion of CTC clusters in the late
stage of metastatic cancer is much higher than previously assumed
[41]. Following studies also demonstrated that CTC clusters, despitetheir rarity, are responsible for seeding ~50e97% of metastatic tu-
mors inmousemodels [42]. This indicates that CTC clusters have 23
to 100 times higher metastatic potential than individual CTCs
[39,42]. Interestingly, single CTCs with the lower metastatic po-
tential could acquire higher metastatic capability when incorpo-
rating with other cells in a cluster [43]. This justifies the critical role
of CTC clusters in cancer metastases. Experiments also revealed
that the detection of only one CTC cluster in blood at any given time
point correlated with significantly lower survival rates in the pa-
tients with prostate, colorectal, breast and small-cell lung cancers
[28,39,44]. Altogether, it is quite likely that CTC clusters play a far
more significant role in the metastasis process than previously
believed.
CTC clusters are not simply a collection of tumor cells. CTC
clusters include some other non-tumor cells such as endothelial
cells, erythrocytes, stromal cells, leukocytes, platelets, and cancer-
associated fibroblasts [39,45e51]. These non-malignant counter-
parts were believed to provide advantages for CTC clusters survival.
Higher metastatic potential of CTC clusters has been reported to be
related to several factors. These factors include the cooperation of
heterogeneous cell phenotypes within the clusters [52], strong
cellecell adhesions, which protect the tumor cells against anoikis
[53], and physical shielding against the attacks of the immune cells
(Fig. 1b) [54].
Despite all the research and hypotheses to date, the rarity of
CTCs in blood sample (1e100 CTCs per 109 blood cells and even
P. Rostami et al. / Journal of Science: Advanced Materials and Devices 4 (2019) 1e18 3fewer CTC clusters) and deficiencies of the existing separation
methods limit our knowledge about CTC clusters. Many questions
about CTC clusters formation, distribution and properties are still to
be answered. To address these questions, an efficient separation
platform is the first step to capture sufficient viable CTC clusters.
Such platform makes subsequent molecular, genetic and biological
analyses possible. Over the past several years, rapid progress in
CTCs research has resulted in the development of technology that
also can separate CTC clusters. However, currently, limited
specialized techniques have been developed for the separation of
CTC clusters.
In recent years, great attention has been paid to CTC clusters
because of their importance in cancer metastases, and the number
of the published articles on CTC clusters has exponentially
increased (Fig. 2). Despite the recent advances and discoveries, CTC
cluster has not yet been reviewed comprehensively. Herein, we
collate many interesting publications to provide a comprehensive
review about CTC clusters from all the related aspects, including
separation methods as well as their clinical applications and pro-
vide scopes for the future research direction.
2. Separation techniques and devices
Rarity is a significant challenge for the separation of CTC clus-
ters. A 10 ml of a peripheral blood sample from a metastatic cancer
patient typically contains 0e100 single CTCs and roughly 0e5 CTC
clusters (only about 5e20% of all CTCs) [39] among approximately
50  109 RBCs, 80  106 WBCs and 3  109 platelets [55]. Another
challenge for CTC cluster separation is possible dissociation during
the blood sample processing. An efficient platform to isolate CTC
clusters would have the capacity to separate intact CTC clusters of
different shape, size, and composition, autonomously of cell surface
markers with minimum manipulation, fast processing time, and
vigorous clinical feasibility and validity. To date, numerous strate-
gies have been developed for isolating single CTCs from blood
sample [56e61] based on the physical (e.g., size, density, deform-
ability, electrophoresis, dielectrophoresis), or biological (e.g., anti-
body expression) differences of CTCs and non-tumor cells.
However, only a few platforms have been developed specifically for
CTC clusters separation. To date, microfluidic devices appear to be
the most encouraging platform for separating CTC clusters, as they
have several unique features, such as the ability to process whole
blood without preprocessing, which results in less cluster dissoci-
ation, fast processing time, and collection of live CTC clusters
without manipulation. Up to now, most studies around clusters




















Fig. 2. The number of articles in “CTC Cluster" & "Circulating Tumor Cell Cluster" in
2000e2016 according to PubMed trend shows that the published articles around CTC
cluster have been increased in recent years.have insufficient efficiency to separate clusters. CTC clusters were
observed fortuitously, using these platforms, which usually
underestimated the number of the CTC clusters due to the limita-
tions of the employed techniques. The platformswith the capability
of isolating CTC clusters are summarized in Table 2 and are briefly
reviewed in this section. Recent progress in active separation
methods can also aid the development of more advanced CTCs-
detecting techniques [62]. Investigating active detection tech-
niques is out of the scope of current paper that focuses mainly on
passive platforms, which are more feasible and have higher po-
tential to be commercialized.
2.1. Antibody-based devices
Antibody-based methods are the most widely used techniques
for CTCs separation. These methods rely on the expression of
cellular surface markers and either isolate cancer cells (positive
selection) or remove normal blood cells, thereby enriching cancer
cells (negative selection). The antibodies mainly pertain to
epithelial cell surface markers that are absent from other blood
cells [63e66]. The epithelial cell adhesion molecule (EpCAM)
Antibody, cytokeratin antibody (anti-CK) and CD45 are the most
common antibodies for distinguishing CTCs and other blood cells.
However, there are still some limitations in these techniques, such
as difficulties in distinguishing between CTCs and non-malignant
epithelial cells [67]. Furthermore, capturing CTCs that have un-
dergone the EMT process cannot be appropriately done using
antibody expression techniques.
One simple technique for detecting and capturing the presence
of CTCs in a blood sample is a high-resolution imaging method. In
this method, blood is first lysed, then the remaining nucleated cells
are plated on a surface and stained with antiEpCAM-fluorescent
antibodies to discriminate cancerous from other cells. However,
this technique is incompatible with the applications that require
the recovery of viable CTCs because the cells are fixed during pro-
cessing. CytoTrack™ solve this issue by developing a pre-scanner
blood sample at high rates (up to 120 million cells/min) and
recorded the potential CTCs targets, and operator can select specific
cells to be isolated by CytoPicker™ for further analyses and
corroboration [68] (Fig. 3a). RareCyte also developed a similar
platform [69]. Commercial Epic CTC Platform (Epic Sciences Inc.,
USA) as another high-speed automated imaging platform uses anti-
CK/CD45/DAPI (40,6-diamidino-2-phenylindole) immunofluores-
cent staining to detect CTCs. The epic platform was reported to be
highly efficient for CTC clusters detection [70]. Ensemble-decision
aliquot ranking (eDAR) () [71,72] is another imaging platform that
uses multi-color line-confocal to identify and enumerate EpCAM
labeled cells. In this platform, a switching mechanism steers posi-
tive aliquot to slits filtration unit and negative aliquot to waste
collection thorough different channels [73] (Fig. 3b). CTC clusters
with low EpCAM expression were observed in the patient blood
samples, utilizing eDAR [73].
Another technique is CellSearch® [26,74,75] (Veridex, USA),
which is a magnetic-activated cell sorting (MACS) method. This
technique is the first and only clinically validated and an FDA-
cleared blood test for CTCs enumeration and separation. In this
method, a 7.5-ml blood sample is centrifuged to separate solid
blood components from plasma. Using magnetic nanoparticles
coated with antibodies to target EpCAM. The cells that have boundTable 1
CTCs, Leukocyte and Erythrocyte size range.
Cell type CTC Leukocyte Erythrocyte
Size Range (mm) 12e30 6e20 4e8
Table 2
CTC cluster separation platforms.
Subcategory Platform Similar methods Separation criteria Key features Throughput Capture efficiency
Microfluidics/Antibody HB-Chip [104] CTC-chip [246], GEDI [102],
GEM [105], OncoBean Chip
[247]
EpCAM Passive micro vortices mix
sample to increase CTC-
antibody-coated surface
15e80 ml/min 79% for spiked single cells/~15%




EpCAM Three modules for separation,
enumeration, and imaging
~160 ml/min 86% for spiked cells/71%
CTC cluster from patient blood
sample
Filtration ISET® ScreenCell® [158] Size/Deformability 8-mm pores filters ~3000 ml/min 43% for single cell in patients
sample/5e100% CTC cluster
from patient blood sample
Filtration FMSA [146] CellSieve® [148], Microcavity
array [154]
Size/Deformability flexible micro spring array,
process whole blood sample
without preprocessing
750 ml/min 76% % for single cell in patients
sample/44% CTC cluster from
patient blood sample
Microfluidics Cluster Chipa [190] cellecell adhesion even two-cell clusters can be
efficiently captured, only
separate CTC clusters
~40 ml/min 30e40% CTC cluster from
patient blood sample
Microfluidics ClearCell® FX [182] Vortex Chip [248], Double
spiral microchannel [249],
eDAR [71]
Size/Inertial Focusing RBC lysis required, easy to
manufacture
~1000 ml/min 100% CTCs in patient samples/
CTC
Cluster observed
Antibody/Image processing CytoTrack [68] FASTcell™ [250], EPIC
platform®, RareCyte [69]
EpCAM Similar capture efficiencies
with CellSearch
Scan 120 M cells/min ~69% for single CTCs in patients
sample/Clusters observed
Antibody CellSearch® [75] Vita-assay™, EasySep® [84],
AdnaTest®, MACS [251],
MagSweeper [252]
EpCAM FDA approved 20e80% for single cells in
patient samples/CTC clusters
observed
Microfluidics DLD Chipa [193] Size/Asymmetry Single and cluster CTCs
separation with 87% viability
~17 ml/min 66e99% CTC cluster capturing
Microfluidics/Antibody 3D scaffold chipa [195] CMx platform [253],
nanostructure coated chip
[254], GO Chip [111]
Size/EpCAM Single and cluster CTCs
separation
50e100 ml/min 80% single cells & 86% CTC
cluster from spiked cells
Antibody CellCollector® [89] EpCAM In-vivo CTCs isolation, CE
approved, large volumes blood
processing
30 min operation time 70% for single CTCs in patients
sample/CTC cluster observed
Centrifugation OncoQuick® Density Porous membrane for
additional separation
~1 h operation time 70e90% single spiked cells/CTC
cluster observation potential
Centrifugation/Antibody RosetteSep® Density/Antibody Negative selection by repulsion
unwanted cells
~1 h operation time 77% single spiked cells/CTC
cluster observation potential








































Fig. 3. Imaging antibody-based techniques of CTC cluster separation. (a) The CytoTrack schematic workflow. Blood sample centrifuged and RBCs lysed, fluorescent antibodies added,
platted on a glass disk. The scanner excited stained cells with a laser at 488 nm and the signals are detected by a photomultiplier tube (PMT). The positions on the disk with possible
CTCs are recorded as hotspots. Then the CytoPicker can isolate the intact cells from the disk. (b) Microfluidic chip and hydrodynamic switching scheme of eDAR platform. When a
CTC was detected by confocal system in blood stream, the blood flow was switched to the CTCs collection channel, in which aliquot is steered to a filtration area with 20,000
microslits. The blood flow was switched back to waste collection channel after the aliquot was sorted. Adapted with permission from ref [73] under the terms of the Creative
Commons Attribution License. Copyright© 2013, American Chemical Society.
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cells are removed [76]. Therefore the CTCs are magnetically sepa-
rated from other blood cells and subsequently identified with the
use of fluorescently labeled antibodies (Fig. 4a) [75]. In CellSearch
method, a CTC cluster is defined as a group, comprising more than
two cells expressing EpCAM, cytokeratins (CKs 8, 18, and 19) and
DAPI without expression of CD45 [25,53,77e83]. There are also
some techniques that use similar CellSearch principle, labeling
CTCs with antigen-specific antibodies linked to magnetic beads like
Dynal Magnetic Beads® (Invitrogen, USA), AdnaTest (Adnagen AG)
(uses a cocktail of antibodies e.g., EpCAM andMUC-1, and AdnaTest
Cancer-type cocktail unlike CellSearch anti-EpCAM antibodies), and
EasySep® (negative selection) (Stem Cell Technologies, Canada)
[84] that CTC clusters have also been observed using them.
Beside CellSearch, Vitatex Inc. developed the cell adhesion
matrix (CAM) assay [85]. The CAM assay exploits the invasive
characteristic of cancer cells in collagen to isolate metastaticinvasive circulating tumor cells (iCTCs). When patient blood sam-
ples are applied to the CAM-coated tubes (Vita-CapTM) or culture
plates (Vita-AssayTM), iCTCs that uptake cell-adhesion matrix
preferentially adhere to CAM (Fig. 4b). This technique separates
CTCs in metastatic prostate and breast cancer [86,87].
The limited blood sample volumes from cancer patients
(5e20ml) may impose a severe restriction on the separation of rare
CTCs. CellCollectors® (GILUPI GmbH, Germany) is a European
Conformity (CE) approved in-vivo CTCs isolation base on antibody
affinity [88]. The system consists of a needle, which is placed
directly in the peripheral arm vein of a patient with up to 1.5 L of
blood pass via an indwelling catheter for 30 min. The flexible
needle is made of stainless steel, a gold coating layer of 2-mm
thickness and a hydrogel coating layer with 2e10 mm thickness. On
the hydrogel layer, antiEpCAM-antibodies are conjugated to iden-
tify and isolate the EpCAM-positive CTCs that can be analyzed in
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Fig. 4. Antibody-based technique of CTC cluster separation. (a) The CellSearch procedure. 7.5 ml of blood sample is centrifuged, plasma removed, added anti-EpCAM-ferrofluid,
incubated in presence of magnetic field then captured cells is analyzed. Adapted with permission from ref [76] under the terms of the Creative Commons Attribution License.
Copyright© 2016 Swennenhuis, J. F. et al. (b) Blood sample lysed then with complete cell culture medium is loaded on Vita-Assay and incubated in CO2 incubator. CTCs are captured
based on their preferential adhesion to CAM. Identification and enumeration of iCTCs can be made by image microscopy and flow cytometry (c) The GILUPI CellCollector is placed
directly into the bloodstream of arm vein via an indwelling catheter for 30 min, captures CTCs by conjugated antiEpCAM-antibodies coated on golden-hydrogel layer.
P. Rostami et al. / Journal of Science: Advanced Materials and Devices 4 (2019) 1e186can detect 70% of CTCs in lung, breast, colorectal and prostate
cancer patients [89e97]. Further studies with other tumors are
currently is in progress.
Methods based on biochemical properties also could be com-
bined with and strengthened by microfluidic technologies [98].
Adams et al. designed a microfluidic device containing a series of
the high-aspect-ratio microchannel (35 mmwidth  150 mm depth)
that were replicated in polymethyl methacrylate (PMMA). The
microchannel walls were covalently decorated with antibodies
directed against cells expressing the EpCAM [99]. Increasing the
throughput of the antibody-based methods, Sequist et al. intro-
duced another microfluidics platform called CTC-chip. A standard
microscope-slide-sized silicon chip with mm-sized posts array that
coated with antiEpCAM-antibodies, to maximize the interaction of
the CTCs with the functionalized surface (Fig. 5a) [100]. The CTC-
chip was able to capture CTC clusters in lung cancer [101]. Geleg-
horn et al. inspired by CTC-chip described geometrically enhanced
differential immunocapturing (GEDI), a theoretical framework for
the use of staggered obstacle arrays to create size-dependent par-
ticle trajectories that maximize prostate circulating tumor cells
(PCTC)-wall interactions while minimizing the interactions of other
blood cells [102,103].
The abundant number and intricate structure of the CTC-chip
microposts presented a challenge for clinical research. Stott et al.
developed amicrofluidic device, herringbone HB-chip. The HB-chip
design utilizes passive mixing of blood cells through the generation
of micro vortices created by angled grooves leading to significantly
increase the number of interactions between target CTCs and the
antibody-coated chip surface (Fig. 5b) [104]. The device was later
optimized geometrically [105]. HB-chip was one of the first
microfluidic platforms that can captures the clusters frommetastatic patient blood samples [106]. Inspired by the HB-chip,
Hyun et al. proposed a geometrically activated surface interaction
(GASI) to increase the surface interaction between the leukocytes
and the anti-CD45 immobilized surfaces for CTCs enrichment
through negative selection [107]. Another group also proposed the
same functionalized surface platform for positive selection,
modular CTC sinusoidal microsystem [108] (Fig. 5c). This micro-
system has a higher recovery rate for CTC clusters and has been
commercialized by BioFluidica.
The principle of enhancing antibodyeCTCs interaction for CTCs
separation has been inspired many similar methods that also have
the potential for CTC clusters separation. Crammed 100e200 nm
pillars were coated with the relevant antibody (anti-EpCAM)
[109,110]. Instead of micropost arrays, some capturing methods
inspired by Stott's work use antibody-coated surfaces to increase
antibody-CTCs interactions [111,112].
One of the major limitations in the positive selection of
antibody-based methods is its inability to target cancer cells with
reduced expression of cancer-associated markers. In the EMT pro-
cess, cells lose their epithelial characteristics and acquire more
mesenchymal-like phenotypes. Consequently, EpCAM expression
significantly decreases, especially in the cells within the clusters
[113]. In addition, EpCAM also can be detected in other diseases
such as benign colon disease can be misinterpreted as cancer cells
[114]. Therefore, such positive detection relying on EpCAM
expression may disregard some critical subpopulations as the
precise number of CTCs may be underrated [115e117]. One idea to
overcome this limitationwas proposed to target the actin-bundling
protein plastin3, a novel marker that is not downregulated by CTCs
during EMT and not expressed in blood cells [118], N-cadherin, O-
cadherin, epidermal growth factor receptor (EGFR), the cytoskeletal
A chip with antiEpCAM-antibodies
coated microposts Staining, differentiates 
leukocytes from CTCs
(a) CTC-Chip (b) HB-Chip
Grooves on channel 
surface






Fig. 5. Enhanced celleantibodies interaction techniques of CTC cluster separation. (a) In CTC-Chip, CTCs are captured against the anti-EpCAM-coated microposts. (b) The HB-Chip
with its grooves on channel surface generates the mixing effect to enhance cellsesurface interaction. Reproduced with permission from ref [104] Copyright© 2018 National
Academy of Sciences. (c) Modular CTC sinusoidal microsystem. This module consisted of an array of high-aspect ratio sinusoidal microchannels with a nominal width of 30 mm and
depth of 150 mm that activated by anti-EpCAM antibodies.
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[103,121]. However, it was reported inexistence vimentin expres-
sion among cells within clusters [122]. In negative selection, leu-
kocytes attachment to CTCs cluster [123] may lead to excluding
precious subpopulation of clusters from detection. In addition,
circulating endothelial cells are CD45, that can exaggerate the
final enumeration of CTC clusters [119]. Another limitation of
antibody-based platforms is the lack of a general marker that could
be used for a variety of cancer cells. Any marker can distinguish
specific tumor cells, but their application is limited by the hetero-
geneity of tumors and, consequently, the different genetic charac-
teristics of the cell even in the same cancer cells [124]. Most
antibody-based separation strategies have generally been
employed towards carcinomas as no specific marker targeting
other cancer types (e.g. Sarcomas) exists so far.
Lately, a new class of CTC-affinitive agents, viz. aptamers,
demonstrated a great potential in the detection of CTCs as an
alternative to antibodies [125e128] with some advantages such as
high affinity, low cost, simple modification, and simple release
mechanisms. Aptamers are synthetic low-molecular-weight single-
stranded DNA/RNA which have been engineered to bind to specific
targets, such as cancer cells with high affinity and selectivity.
Aptamers can bind to cell membrane targets [129,130], and can also
be selected against whole cancer cells [131]. Some research groups
developed microfluidics-based cell-affinity devices to capture CTCs
using aptamers [132e134].
Consequently, in antibody-based methods, the prevalence of
CTC clusters was rare [64]. In general, the efficiency of antibody-
based methods chiefly depends on two factors: the expression
and specificity of the target antigen and the affinity between an-
tigens and antibodies, and the efficiency of labeling process.
Compared to single CTCs, CTC clusters have smaller surface-to-
volume ratios, which reduce the efficiency of antibody-based
platforms to detect clusters that can be more obvious in larger
CTC clusters [135]. Although antibody-based methods have been
used widely for CTCs separation, there are still some drawbacks,such as high cost and the need precise procedure, which pose
challenges for using them pervasively in CTCs detection for clinical
applications.
2.2. Physical property-based devices
Differences in physical properties such as cell density, size, and
deformability, can be utilized to separate CTCs and CTC clusters. For
instance, CTCs can be separated by filtration due to their larger size
compared to other blood cells (Table 1). Most separation platforms
based on physical properties use microfluidic technologies.
Microfluidic platforms not only provide better efficiency in CTCs
separation [136] but also facilitate the integration and the auto-
mation of high-throughput low-cost sample processing to achieve
a real lab-on-chip solution [137].
Based on the assumption that CTCs especially CTC Clusters are
larger than other blood cells (Table 1), microfiltration techniques
demonstrate a great potential for attaining high throughput anal-
ysis of sample volume. ISET® (isolation by size of epithelial tumor
cells) (Rarecells diagnostics, France) is developed based on trapping
the major epithelial cells (20e30 mm) while passing other cells
(6e12 mm) through the pores of predefined size and shape. ISET®
used a module of filtration (10e12 well) containing polycarbonate
track-etch-type membrane, which comprises numerous randomly
distributed 8-mm-diameter, cylindrical pores to separate CTCs from
blood cells through size and deformability (Fig. 6a) [138]. RareCells
claims that ISET® sensitivity threshold is one CTC in 10 ml of blood.
ISET® platform also was demonstrated to be able to separate CTC
clusters in different metastatic cancer [139e145]. However, such
filtration platforms also retain some larger non-tumor cells, which
is why this techniques are considered not very specific. CTC clusters
from liver and lung cancers captured by ISET® are undetectable by
CellSearch, shows more sensitivity of ISET® for CTC clusters sepa-
ration than antibody-based methods [53,115].
Another microfiltration platform, called FMSA (flexible micro
spring array), enriches CTCs based on their size and deformability.
+ISET buffer
ISET device Filtration























Staining and downstream 
analysis
(c) CellSieve 
Fig. 6. Filtration techniques of CTCs separation. (a) ISET: 10 ml of blood are diluted, treated with the filter. (b) FMSA setup schematic: it enriches CTCs based on their size and
deformability. (c) CellSieve™ microfilters, a 10 mm thick modified SU-8 polymer film with an array patterned filter with 7 mm diameter pores. Reproduced with permission from ref
[150] under the terms of the Creative Commons Attribution License. Copyright© 2017 Hayashi et al.
P. Rostami et al. / Journal of Science: Advanced Materials and Devices 4 (2019) 1e188FMSA is a 0.5 cm2 filtration membrane with a novel micro spring
geometry, which was designed to maximize the throughput and
allows for prompt CTC enrichment directly from peripheral blood
sample without preprocessing [146]. Blood sample passed through
the FMSA device under accurately controlled pressures. Cells with a
specific size are trapped in FMSA plate. The platform then uses
antibodies for immunofluorescent detection. CTC clusters were
separated from 44% of 7.5-ml whole blood clinical samples of
breast, lung, and colorectal cancer in <10 min (Fig. 6b) [146,147].
CellSieve™ is another filtration platformwith ~160,000 5e9 mm
pores, spaced at 20 mm intervals [148,149] (Fig. 6c). It was reported
detection of CTC clusters in sarcoma patients using CellSieve™
[150]. CTC cluster separation method based on physical properties
can be also combined with and strengthened by microfluidic
technology, leading to other microfiltration and microcavity plat-
forms [151], as introduced by Mohamed, Tan, Xu and Zheng and
others [152e157] that have potential for CTC clusters separation
[158]. Among shortcomings associated with filtration platforms,
clogging is one of the most critical one [159]. Some groups rectified
clogging problem of filtrationmethods by developing a filter device
that could periodically be cleared [160] or by geometrical optimi-
zation microcavity [161]. Filtration platforms allow direct filteringof peripheral blood samples without preprocessing and are more
cost-effective compared to antibody-based methods [162]. How-
ever, the intense tension stress and a mechanical lesion at the pore
edges of the microfiltration techniques could cause deformation
and remodeling [163] that affect the viability and integrity of cells,
especially in CTC clusters, thus making the majority of them not
suitable for further biological analysis [164].
Centrifugation is one of the earliest strategies for CTCs separa-
tion [165]. OncoQuick® (Greiner Bio-One, Germany) as a CTCs
separation platform is based on density gradient centrifugation
[61]. The kit includes a 50 ml tube that is separated into two sec-
tions by a porous barrier. The lower section contains the separation
medium which prevents blood from mixing with the gradient
before centrifugation. The upper section accommodates up to 30ml
of the blood sample for processing. During centrifugation, the cells
are separated according to their densities. The denser blood com-
ponents such as red blood cells and white blood cells migrate
through the porous barrier into the lower section. Less dense cells,
including the CTCs, settle at the interphase layer between the
separationmedium and the plasma in the upper section [166]. After
washing steps, the captured CTCs can be used for further analyses

















































Fig. 7. Centrifugation techniques of CTCs separation. (a) OncoQuick workflow schematic: the cells are separated according to their different buoyant densities. Reproduced with
permission from ref [166]. Copyright© 2018 Greiner Bio One International GmbH. (b) RosetteSep workflow schematic: Unwanted cells are cross-linked to RBCs by specific anti-
bodies, forming dense immunorosettes. Reproduced after StemCell. Copyright© 2018 STEMCELL Technologies Inc.
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less accurate and less sensitive in CTC enumeration as compared
with CellSearch [169]. Some clinical studies have utilized Onco-
Quick for CTCs enrichment [170e173], CTC clusters were observed
in some of their results.
A more advanced density gradient centrifugation technique is
the RosetteSep® (Stem Cell Technology, Canada), which is based on
the negative selection. RosetteSep® is a physical-biochemical-based
method where antibodies crosslink a variety of unwanted cells,
specifically leucocytes and RBCs, forming aggregates termed ‘ro-
settes’. The ‘rosettes’ sediment in the erythrocyte layer during the
centrifugation step using a gelatin density gradient. The CTCs are
negatively enriched in the mononuclear layer (Fig. 7b) [174].
Centrifugal spiral microfluidic devices utilize inertia and the
Dean flow [175e178] for CTCs separation. These microchannels
have been designed with various cross-section geometries such as
the rectangular [179,180], trapezoidal [181,182] and the stair-like
[183] configurations. Two contrary inertial force (FL) and shear
gradient force (FW) are dominant on particles with size ratio a/
h > 0.1 (where a is particle diameter and h is channel height), while
the secondary flow (Dean vortex) in curvilinear channels controls
the movement of smaller particles. Inertial lift forces confine CTCs
to a specific region of the channel cross-section, while smaller
blood cells continue to be entrained along the Dean vortices. Using
this method, CTCs and blood cells are focused to distinct streams
within the microchannel and can be collected through two sepa-
rate outlets. The throughput of these devices is shown to be
reasonably high (as 7.5 ml of blood per 8min) with high separation
efficiency [182]. These devices are also used for cell retention in
perfusion culture flask [184], cell fractionation, and filtration [185].
Hou et al. developed a spiral microchannel with intrinsic dean drag
and inertial lift forces for size-based separation of CTCs from the
blood sample. Dean flow fractionation (DFF) platform facilitates
simple coupling with downstream biological assays of cancer cells
(Fig. 8) [179].
A year later Warkiani et al. upgraded the DFF platform with a
trapezoidal cross-section (ClearCell® FX) [182] for ultra-fast label-
free CTCs separation from peripheral blood samples using the Deandrag force coupledwith the inertial lift force. This technique utilizes
the intrinsic Dean vortex present in a curvilinear microchannel,
along with inertial lift forces that focus large cells like CTCs against
the inner wall to separate cancer cells based on size. The trape-
zoidal cross-section, averse to the common rectangular cross-
section, can alter the core position of the Dean vortex, to achieve
more effective separation (Fig. 8). With upgraded DFF, single CTCs
and clusters successfully were isolated.More than 80% of the spiked
cancer cells were recovered from7.5ml of bloodwithin 8min [182].
This method is particularly attractive because of its simplicity and
the high processing rates, approximately 0.5e1 ml/min for RBC-
lysed blood samples. The high throughput makes DFF beneficial
for applications that require the isolation of CTCs from large vol-
umes of blood, such as early detection. Recently, using this device,
CTC clusters were observed in the head and neck cancer [186].
Clusters are on average larger than individual CTCs and healthy
blood cells. However, strategies that rely solely on size-based
separation may have limitations when applied to CTC clusters.
The majority of clusters consist of 2e4 individual CTC. Individual
CTC size varies dramatically, ranging from 12 to 30 mm evenwithin
the same patient [187,188]. This overlap size range of large single
CTCs and leukocytes (~6e20 mm) with clusters (Table 1) [189] can
lead to reducing the size disparities of most clusters with large
singles and leukocytes. On the other hand, clusters often assume
alignments that mask their most extended axes during size-based
separation [55].
Some technique discussed so far have been designed and
developed specifically for separation single CTCs. CTC clusters were
incidentally observed in many of these single CTC isolation plat-
forms. Addressing the drawbacks of these platforms, Sarioglu et al.
fabricated an exclusive platform for separation of intact and viable
CTC clusters [190]. The team developed the Cluster-Chip, to capture
CTC clusters independently of tumor-specific markers from the
unprocessed blood. CTC clusters are isolated through bifurcating
triangular pillars as traps under loweshear stress conditions that
preserve their integrity. The Cluster-Chip captures CTC clusters by
relying on their cellecell junction (Fig. 9a). This platform is able to


































Fig. 8. Inertial focusing technique of CTCs separation. CTCs focused near the inner wall due to the combination of the inertial lift force and the Dean Drag force while white blood
cells and platelets are trapped inside the core of the Dean vortex formed closer to the outer wall. Reproduced with permission from ref [179,182] under the terms of the Creative
Commons Attribution License. Copyright© 2013 Springer Nature Limited. Copyright© 2018 Royal Society of Chemistry.
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2.5 ml/h [190]. The recovery of clusters immobilized on micropillar
arrays is challenging due to the requirement of an operation tem-
perature of 4 C and flow with shear stress greater than physio-
logical one for releasing the CTC clusters [55]. Recently Inspired by
Cluster chip Gao et al. amended an earlier size-based CTC separa-
tion platform [191], which captured CTC clusters and single CTCs
separately [192].
To address this limitation, Au et al. proposed a two-stage
continuous microfluidic chip that separates intact CTC clusters
from blood samples [193]. This platform designed to utilize deter-
ministic lateral displacement [194] to sort clusters based on geo-
metric properties such as size and asymmetry. The first stage
separates larger clusters based solely on their large size; using
standard cylindrical DLD micropillar arrays to deflect particles with
shortest axial diameters of 30 mm or more. The second stage was
designed with asymmetric hybrids of elliptic cylinders and “I”-
shaped pillars with the 30 mm ceiling. The second stage imposes the
clusters that failed to be captured in the first stage to align their
longitudinal axes “flat” in the flow direction (XeY plane) (Fig. 9b).
Therefore, the second stage sorts CTCs by discriminating asym-
metric clusters from symmetric single cells. This strategy isolates
99% of clusters containing 9 or more cells and 66% of smaller
clusters from whole blood. In a DLD-Chip, CTC clusters experience
physiological or even lower shear stress and have short residence
times. This platform separates clusters with over 87% viability and
unhindered proliferation abilities. However, this strategy is limited
by its relatively slow blood flow rate of 1 ml/h.Another microfluidic device deliberately designed to isolate CTC
clusters is “antibody-functionalized 3D scaffold gelatin-microchip”,
which can efficiently separate clusters by combining antibody
recognition and physical barricade effect of the scaffold structure
[195,196]. Improving capture efficiency of marker-dependent stra-
tegies by CTCs-antibody interaction increment idea [197], Cheng
et al. coated the 3D PDMS scaffold with multiple thermosensitive
gelatin layers and functionalized it with anti-EpCAM antibodies.
This scaffold with porous structure generates uncontrolled migra-
tion of cells that leads to increasing cellestructure interaction. After
pumping blood sample into the scaffold chip at a flow rate of 50 ml/
min to capture CTCs, gelatin hydrogel dissolves at physiological
temperature (37 C) and washing with PBS (Phosphate-buffered
saline), allowing the cell-friendly release of CTCs for further anal-
ysis (Fig. 9c). Using this microchip, free individual and cluster CTCs
were successfully obtained from the blood sample of cancer pa-
tients. This platform captured more than 88% of MCF-7 single CTCs
with 60e70% recovery ratio and 82%e100% of two-to over nine-cell
cluster with 50e100% recovery ratio respectively, with the high
viability of more than 90% [195].
2.3. Additional CTC clusters separation & detection techniques
Besides all the platforms mentioned above, some additional
methods have been developed to detect or separate CTC clusters.
Ge et al. proposed a novel strategy integrating subtraction enrich-
ment and immunostaining-FISH (SE-iFISH®) (immuno-fluores-



























PDMS scaffold Thermosensitive gelatin & anti-
EpCAM coating
Separate CTCs PBS washing at 37°C
Analysis
(b) DLD Chip
(c) Antibody-functionalized 3D scaffold gelatin-microchip
Fig. 9. Exclusive CTC cluster separation methods. (a) Operation of the Cluster-Chip. CTC clusters captured, whereas single cells pass through multiple rows of shifted triangular
pillars that form consecutive cluster traps. Scale bars is 60 mm. Reproduced with permission from ref [190]. Copyright© 2015, Springer Nature. (b) Two-Stage DLD Chip operating
Principles; array of cylindrical micropillars in first stage (AeA top view) deflects large clusters; while asymmetric pillars in second stage (BeB top view) deflects small clusters.
Reproduced with permission from ref [193] under the terms of the Creative Commons Attribution License. Copyright© 2017 Au et al. (c) Scheme of capturing and release of in-
dividual and cluster CTCs using “antibody-functionalized 3D scaffold gelatin-microchip”. Reproduced with permission from ref [195]. Copyright© 2017, American Chemical Society.
P. Rostami et al. / Journal of Science: Advanced Materials and Devices 4 (2019) 1e18 11effective depletion of WBCs RBCs by immunomagnetic and
centrifugation, to establish a high-throughput detection of CTCs
irrespective chemical markers and physical properties. The SE-
iFISH platform was able to efficiently detect CTC clusters from
prostate cancer [199].
A photoacoustic technique exploits strong optical absorption
of melanin to image and sense melanoma CTCs in vivo. This
platform utilized linear-array-based photoacoustic tomography
(LA-PAT) technique for label-free high-throughput in-vivo CTC
cluster detection. In addition, LA-PAT can quantify the number of
cells in the CTC clusters and study their kinetics in the blood
circulation by analyzing the contrast-to-noise ratios of the pho-
toacoustic signals [200].
Jiang et al. utilized both physical and biological properties of CTC
clusters to introduce a new isolation technique treats platelets as a
marker for the separation of platelet-cloaked CTC clusters. In this
method, CTCs were targeted by capturing platelet-covered cells.
This platform incorporated a two-step microfluidic strategy. Thefirst step depletes free platelets by size, using deterministic lateral
displacement (DLD). The second step isolates platelet-covered
clusters, using the herringbone CTC chip (HB-Chip), which as
mentioned induces micro vortices to enhance cell-capture surface
interactions. This platform enabled the separation of CTCs from
~60% of epithelial lung and breast cancer, and also 83% of mesen-
chymal melanoma cancer [201].
Ozkumur et al. developed a three-step strategy that combines
microfluidics andmagnetic-based inwhich small CTC clusters were
observed [202]. After the magnetic labeling of cells in whole blood,
DLD was used to deplete RBCs, platelets, and other small blood
cellular debris from the sample. Next, inertial focusing was utilized
to align nucleated cells within a microfluidic channel by intro-
ducing asymmetrically curved channels. These Channels help to
extenuate the cellular collisions and ensure cellular displacement
only as a function of magnetic force in the next step. At the last step,
CTCs (positive selection) or WBCs (negative selection) immuno-
magnetically deflect into the collection channels.
Table 3
CTC cluster clinical applications.
Subcategory Clinical significance Type of cancer reference
Prognosis and diagnosis The presence of CTC clusters is associated with
worse clinical outcome (PFS & OS)
Breast cancer [39,206e209,213,239,255]
Prostate cancer [39]





Pancreatic ductal adenocarcinoma [211]
The presence of CTC clusters is associated with
larger primary tumor and metachronous
development of lung metastases
Renal cancer [256]
Molecular & Genomic analysis Studied on EGFR, KRAS, and PIK3CA gene inhibition
with therapeutic purposes
Colorectal cancer [218]
Mutations in the KRAS and EGFR genes relevant for
treatment decisions
Lung cancer [90]
Reported EGFRVIII expression on CTCs by molecular
analysis
Squamous cell carcinoma of head and neck [41]
Sequence whole exomes of CTCs Prostate cancer [220]
EML4-ALK gene rearrangement Lung adenocarcinoma [222]
Therapeutic and drug Increment CTC cluster number in non-responder
chemotherapy patients
Colorectal cancer [235]
Antioxidant genes testing as amethod for treatment
monitoring
Prostate cancer [228]
Chemotherapy resistance of the circulating tumor
cell clusters
Colon cancer [63]
Developed a microfluidics platform for study tumor
celledrug interactions and drug responsiveness
Breast cancer [233]
Elevation circulating tumor cell number correlates
with macroscopic progression of primary tumor
Colorectal cancer [235]
Study CTCs and response to chemotherapy Breast cancer [237,238]
CTC cluster dissociating and metastatic condition Breast cancer [123]
Studying enzalutamide, everolimus and BKM-120 Prostate cancer. Renal cell cancer [245]
In situ drug screening on patient-derived CTC
clusters
Breast cancer [236]
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CTCs can be used for various clinical purposes, e.g., examine the
cancer cells respond to therapeutic regimes, predict overall sur-
vival, noninvasively drug susceptibility monitoring, metastatic
therapy and as early cancer detection and diagnostic biomarkers.
Due to the higher metastatic potential, CTC clusters serve as a
noninvasive method with high potential for diagnosis, prognosis,
and treatment inmany academicals studies and clinical trials. In the
following sections, we discuss experimental attempts of using CTCs
in a clinical context (Table 3). According to ClinicalTrials.gov there
have been more than 400 recruiting clinical trials that utilize CTCs
up to January 2019. The extreme effort is required on CTC clusters
applications.
3.1. Prognosis and diagnosis
Conventional tumor biopsy posses disadvantages such as
sampling bias, sampling difficulty, and harm to patients. Since
CTCs are present in the peripheral blood of carcinogenesis cancer
patients even in the early stage [203], detection them from blood
sample, especially CTC clusters due to their higher metastatic po-
tential, as liquid biopsy could be a great alternative to conventional
tumor biopsy [204] for cancers prognosis and diagnosis. Recent
experimental studies have revealed a direct and robust association
between the presence of CTC clusters recovered from venous pa-
tient blood and the significantly reduced survival rate as well as
lousy prognosis in some types of cancer [28,38,205e210]. Re-
searchers also demonstrated the correlation of CTC clusters
number present in a blood sample with worse progression-freesurvival (PFS) and overall survival (OS) [39,152,209,211e213], but
any correlation between the number of CTC clusters and tumor
type or stage [38,63,214,215]. However, in a recent study, the
presence of CTC cluster in a blood sample of the patient was
correlated with resistance to therapy in epithelial ovarian cancer
(EOC) [216].
3.2. Molecular and genomic analysis
The molecular analysis of CTCs facilitates the identification of
themolecular drivers of cancer in the patient body [217]. In a recent
work, molecular profiling of epidermal growth factor receptor
variant type III (EGFRVIII) was shown to be a good indicator of
squamous cell carcinoma of head and neck [41]. After the immu-
nohistochemical analysis, EGFRVIII expression observed in CTCs of
a patient, also was detected in the primary and the metastatic tu-
mors of the same patient [41]. In a study of Gasch et al. [218], the
mutations of PIK3CA, KRAS, and BRAF genes were analyzed using
Sanger sequencing for predicting the resistance against anti-EGFR
therapy in five patients. The PIK3CA gene displayed two different
mutations in two separate CTCs in a patient, which indicates the
CTC analysis capability to inform us about the tumor mutational
heterogeneity. Using sensitive deep-sequencing genomic analyses
of CTCs in patients with prostate and colorectal cancer demon-
strated that mutations in CTCs resemble mutations in both the
primary tumor and metastases [119,219e221]. Zhang et al. recently
utilized CTCs-derived organoids in genetic analyzing of lung
adenocarcinoma CTCs to detect ALK instability and rearrangement
[222]. Therefore, relinquish these mutations in therapeutic regimes
can affect the efficacy of drugs against mutinied targets [223,224].
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Recent studies have specified that CTCs could be used in
frequent genetic profiling to monitor the evolving mutational
outlook and drug sensitivity patterns for individual patients
[222,225e227]. Giesing et al. showed antioxidant genes of CTC
clusters analyzing as a novel method with superb prognostic and
predictive properties for monitoring treatment regime [228]. The
authors suggested that the antioxidant genes helps CTC clusters as
a survival and defence mechanism in confronting with immune
surveillance.
Recently, CTC-derived organoid cultures have emerged as a
novel technique inmedical research and precisionmedicine as they
preserve tumor tissue heterogeneity and drug-resistance re-
sponses, and thus are suitable for high-throughput drug screening
[229,230]. CTC-derived organoids could help to identify mutations
in CTCs and epigenetic information about tumors, and screen
treatment regimes in real time [63,227]. Some groups recently have
developed microfluidic platforms to study tumor celledrug in-
teractions were assessed. Subsequently, the pharmacological effi-
cacy of chemotherapeutic drugs [231,232], tumor cells for drug
responsiveness [233] and resistance [234] were monitored. Molnar
et al. demonstrated that the CTC clusters number in blood sample
reflects the chemotherapeutic sensitivity in colorectal cancer [235].
Recently, Khoo et al. developed a platform to evaluate drug
response on CTC clusters using patient-derived CTCs cultures. The
team designed tapered microwells on microfluidics platform to
allow CTC clusters formation without pre-enrichment and subse-
quent drug screening in situ [236]. In addition, the elevation of CTCs
number in peripheral blood is associated with macroscopic pro-
gression of tumor. Another study [237,238], demonstrated that
CTCs number (5 per 7.5 ml blood) with and without CTC cluster
[239] after the first chemotherapy could be a biomarker of disease
progression and monitoring of treatment strategy. The authors
proposed that the patients with unchanged blood levels of CTCs
represent cancer cell resistance to the adopted therapy, so they
should shift to other treatment regimes.
The improvement of long-term survival is still disappointing.
For most of the approved new cancer drug regimens, the survival
time is only 1e2 months [240,241]. A major reason for these
modest gains is that these drugs were not developed to directly
target agents responsible for metastasis [63], especially CTC clus-
ters [242]. A novel strategy for combating metastasis could be to
dissociate CTC clusters into less potent individual CTCs in the cir-
culation (e.g., by weakening the adhesion energies between cancer
cells within clusters). Choi et al. tried such a strategy practically
using urokinase [123,243]. The authors claimed that urokinase
could lyse fibrin to dissociate CTC clusters and as a result reduced
the prevalence of metastasis in animal models. In addition, they
demonstrated a reduction in the number of CTC clusters that
incubated with urokinase in vitro. In-vivo urokinase utilizing in the
blood of treated mice showed a decreased number of CTC clusters
compared to the control. Therefore, the results suggest that uro-
kinase disintegrates CTC clusters into individual CTCs [123]. How-
ever, some researchers do not agree with disaggregation of CTC
clusters in the bloodstream as a metastasis treatment. They caution
that urokinase treatment may also include the risk of increasing
invasiveness of tumor cells and metastatic spreading, resulting in
the opposite effect of that, as reported by Choi et al. [244].
In the field of cancer drug development, Gao et al. used CTCs-
derived organoids for testing the new version of androgen recep-
tor antagonist (enzalutamide) and PI3K-kinase pathway inhibitors
(Everolimus and BKM-120) [245].
Overall, despite of all experimental studies in CTC cluster,
currently, the clinical importance of CTC clusters remains elusive.Further study is requisite to exploit the full potential of CTC clusters
in real-world clinical applications.
4. Conclusions and outlook
CTC cluster analysis as a noninvasive liquid biopsy is a new
expanding field that can introduce unprecedented horizon in early
cancer diagnosis and therapy assessment in clinical trials. Never-
theless, due to inefficient separation platforms and heterogeneous
biology, there are still many fundamental unsolved issues about
CTC clusters. As such, to date, it is not clear the metastatic potential
of included tumor cells in a cluster compared to single CTCs and the
effect of CTC cluster size and cell number on its metastatic poten-
tial. Whether dissociating CTC clusters into single CTCs can effec-
tively reduce their metastatic risk. How the associated non-tumor
cells included in CTC clusters increase their survival and more
efficient distant colonization, as well as CTC cluster collective
migration are among the outstanding questions in CTC cluster
biology.
Despite the significant progress in separation methods, sub-
stantial work still needs to be done to achieve a platform to effi-
ciently identify, enumerate, and isolate intact CTC clusters in a
reasonable time with minimal manual intervention. Subsequent
developments in CTC cluster separation technologies will enhance
our knowledge about these multicellular aggregates and their
contribution to metastasis progression and can translate
laboratory-based concepts to clinical applications in real-world
settings. Complementary studies should be undertaken to charac-
terize CTC clusters and to utilize their clinical value.
Monitoring treatment regime is a great potential field of interest
toward individual treatment. Therefore, the next step after devel-
oping an efficient separating platform for CTC cluster is ex-vivo
patient-derived CTCs culturing. However, to date, no techniques
have been presented for CTC clusters culturing. The future research
should focus on developing strategies for long-term culture of
patient-derived CTC clusters.
Due to their higher metastatic potential, CTC clusters are ex-
pected to be utilized broadly in cancer and metastasis clinical
trials in the coming years. We envision that liquid biopsy and
qualitative and quantitative monitoring of CTCs, especially CTC
clusters, will allow the clinician to establish more effective
personalized treatments.
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